Melinta Therapeutics (United States)
Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital settings. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Melinta Therapeutics (United States), United States, covering academic research published from 2002 to 2024. Read More.
Open Access Percentage
67%
Total
Publications
163
Total Open
Publications
110
Total
Citations
4.7K
Open Access
Percentage
67%
Total
Publications
163
Total Open
Publications
110
Total
Citations
4.7K
Breakdown
Publisher Open
22%
Both
37%
Other Platform Open
8%
Closed
33%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 53%
51
Hybrid 29%
28
No Guarantees 18%
18
Other Platform Open
Domain 86%
64
Public 27%
20
Institution 7%
5
Preprint 3%
2
Other Internet 1%
1
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 64 |
Europe PMC | Domain | 40 |
Semantic Scholar | Public | 20 |
DOI | Other Internet | 10 |
Radboud University - Radboud Repository | Institution | 2 |
bioRxiv | Preprint | 2 |
University of Udine - Institutional Research Information System | Institution | 1 |
University of Massachusetts Amherst - ScholarWorks@UMassAmherst | Institution | 1 |
Universitat Pompeu Fabra - Repositori digital de la UPF | Institution | 1 |
Universitat Autònoma de Barcelona - Dipòsit Digital de Documents de la UAB | Institution | 1 |